

Filed on behalf of Novartis AG

By: Jane M. Love, Ph.D., Reg. No. 42,812
Robert W. Trenchard
GIBSON, DUNN & CRUTCHER LLP
jlove@gibsondunn.com
rtrenchard@gibsondunn.com
Tel.: 212-351-3922
Fax: 212-351-6322

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ARGENTUM PHARMACEUTICALS LLC,
Petitioner

v.

NOVARTIS A.G.,
Patent Owner.

Case IPR2017-01550

Patent 9,187,405

NOVARTIS' MOTION FOR ADMISSION *PRO HAC VICE* OF
ROBERT W. TRENCHARD

I. Statement of Precise Relief Requested

Novartis AG (“Novartis”) hereby respectfully requests that the Patent Trial and Appeal Board (the “Board”) admit Robert W. Trenchard *pro hac vice* in this proceeding under 37 C.F.R. § 42.10(c). Good cause exists for the Board to grant Novartis’s motion.

II. Statement of Facts Showing Good Cause for the Board to Recognize Counsel *Pro Hac Vice* During the Proceeding

Under 37 C.F.R. § 42.10(c), the Board may admit counsel *pro hac vice* for good cause, so long as lead counsel is a registered practitioner and subject to any other conditions the Board requires. Under Section 42.10(c), good cause includes when “counsel is an experienced litigating attorney and has an established familiarity with the subject matter at issue in the proceeding.”

This application satisfies the requirements of Section 42.10(c):

1. Lead counsel, Jane M. Love, Ph.D., the undersigned, is a registered practitioner.
2. Mr. Trenchard is an experienced litigator and has an established familiarity with the subject matter at issue here, as shown in his accompanying June 29, 2017 Declaration (“Trenchard Decl.”), Ex. 2001. That declaration shows that Mr. Trenchard has been a litigator for 22 years. He is a member in good standing of the New York and New Jersey State Bars, and is also admitted in several federal

courts. He is familiar with the subject matter of this case, including U.S. Pat. No. 9,187,405 (“the ‘405 patent”), the patent’s prosecution history, the underlying technology, and the prior art cited by the petitioner in this matter. Trenchard Decl. ¶¶ 9-10 (Ex. 2001).

3. In his declaration, Mr. Trenchard also attests to each of the listed items required by the Order – Authorizing Motion for *Pro Hac Vice* Admission – 37 C.F.R. § 42.10 in IPR2013-00639. See Trenchard Decl. ¶¶ 1-13 (Ex. 2001).

III. Conclusion

For the foregoing reasons, Novartis respectfully requests that the Board admit Robert W. Trenchard *pro hac vice* in this proceeding.

Respectfully Submitted,

/Jane M. Love, Ph.D./

Jane M. Love, Ph.D.
Registration No. 42,812
GIBSON, DUNN & CRUTCHER LLP
200 Park Avenue
New York, NY 10166
Jlove@gibsondunn.com
Tel.: 212-351-3922
Fax: 212-230-8888

Dated: June 29, 2017

Certificate of Service

The undersigned certifies she did cause to be served true and correct copies of the following:

- Novartis' Motion for Admission for Robert W. Trenchard *Pro Hac Vice*
- Declaration of Robert W. Trenchard in Support of Motion for Admission *Pro Hac Vice* (Exhibit 2001)

to be served via email on the following attorneys for Petitioner:

Teresa Stanek Rea: TRea@Crowell.com
Deborah H. Yellin: DYellin@Crowell.com
Shannon M. Lentz: SLentz@Crowell.com

Crowell & Moring LLP
Intellectual Property Group
1001 Pennsylvania Ave, NW
Washington, DC 20004-2595
Telephone: (202) 624-2500

Tyler C. Liu: TLiu@agpharm.com

Argentum Pharmaceuticals, LLC
Telephone: (202) 749-8605

Dated: June 29, 2017

/Jane M. Love, Ph.D./
Jane M. Love, Ph.D.
Reg. No. 42,812
Lead Counsel for Patent Owners